Study in Asia of the Combination of TACE With Sorafenib in HCC Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

TACE possibly plays a significant role in contributing to a subgroup of surviving residual tumor tissue which is characterized by more aggressive biology. This explains the strong scientific rationale for exploring the role of anti-angiogenic therapy such as sorafenib to remedy and strengthen the therapeutic efficacy of TACE to combat liver cancers. Sorafenib plays a prominent auxiliary role by further suppressing the tumor growth and prolonging the time to recurrence and progression. Performing TACE under sorafenib administration may have synergic effect on hepatic tumoral lesions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sorafenib Chemoembolization Evaluation Controlled Trial

NCT01906216

Hepatocellular Carcinoma

COMPLETED PHASE3

Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma

NCT03066557

Hepatocellular Carcinoma

UNKNOWN NA

TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma

NCT04103398

Hepatocellular Carcinoma Sorafenib Transarterial Chemoembolization

COMPLETED PHASE3

TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma

NCT01869088

Hepatocellular Carcinoma

UNKNOWN PHASE3

TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma

NCT02529761

Hepatocellular Carcinoma

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sorafenib

Group Type EXPERIMENTAL

doxorubicin

Intervention Type DRUG

After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)

TACE (Transcatheter arterial chemoembolization)

Intervention Type PROCEDURE

TACE (Transcatheter arterial chemoembolization)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

doxorubicin

After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)

Intervention Type DRUG

TACE (Transcatheter arterial chemoembolization)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≧ 18
* life expectancy \> 12 weeks
* Histologically diagnosed HCC, OR clinically diagnosed HCC for patients with difficulty in obtaining histological diagnosis. A clinically diagnosed HCC should fulfill ALL the criteria below

* Chronic hepatitis B or C and/or evidence of liver cirrhosis.
* Presence of hepatic tumour(s) with image findings compatible with HCC, and no evidence of other gastrointestinal tumours
* A persistent elevation of serum AFP \>= 400 ng/ml without any evidence of an existing α-fetoprotein-secreting germ cell tumour
* Child-Pugh score ≦ 7
* BCLC B
* The patient must have a solitary hepatic tumour greater than 3 cm in diameter or multifocal disease as evidenced by CT or MRI scanning.
* The target lesion must not have been previously treated with local therapy
* The patient must not be a candidate for surgical resection or ablation of the tumour. Size of largest tumor ≦10cm in largest dimension
* Patients who have received previous local therapy treatments (RFA, PEI, cryoablation, surgery, resection) to non-target lesions are eligible
* Local therapy must have been completed at least 4 weeks prior to baseline scan.
* ECOG performance status 0 or 1
* Hb ≧ 9g/dL,
* Absolute neutrophil count \> 1000/mm3
* Platelet count ≧ 60x109/L
* Adequate clotting function: INR \< 1.5
* Hepatic: AST or ALT \< 5 X ULN
* Renal: serum creatinine \< 1.5 x ULN
* Bilirubin ≦ 3mg/dL
* The patient must give written, informed consent

Exclusion Criteria

* Tumor factors

* Presence of extrahepatic metastasis
* Predominantly infiltrative lesion
* Diffuse tumor morphology with extensive lesions involving both lobes.
* Vascular complications

* Hepatic artery thrombosis, or
* Partial or complete thrombosis of the main portal vein, or
* Tumor invasion of portal branch of contralateral lobe, or
* Hepatic vein tumor thrombus, or
* Significant arterioportal shunt not amenable to shunt blockage
* Liver function

* Advanced liver disease: ascites, hepatic encephalopathy
* Patients with clinically significant gastrointestinal bleeding within the 30 days prior to study entry.
* Others

* Pregnant or lactating women.
* Active sepsis or bleeding.
* Hypersensitivity to intravenous contrast agents.
* The patient has received prior treatment for HCC target lesion.
* History of cardiac disease

* Congestive heart failure \> NYHA class 2; active coronary artery disease
* Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.
* Hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg despite optimal medical management.
* Therapeutic anticoagulation with coumarin, heparins, or heparinoids.
* Serious non-healing wounds (including wounds healing by secondary intention), acute or non-healing ulcers, or bone fractures within 3 months.
* Impairment of swallowing that would preclude administration of sorafenib.
* The patient is, in the opinion of the investigator, unable and / or unwilling to comply with treatment and study instructions.
* Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated \> 3 years prior to entry is permitted
* Any active clinically serious infections (\> grade 2 NCI-CTCAE ver 3.0)
* HIV infection or AIDS-related illness or serious acute or chronic illness (based on medical history)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No